AS04-adjuvanted semisynthetic glycoconjugate vaccine against Pseudomonas aeruginosa.
The immunogenicity limitation has underscored the critical need for human vaccine adjuvants that can elicit potent and durable humoral and cellular immunity tailored to semisynthetic glycoconjugates. To circumvent the toxicity of Freund's adjuvant (FA) and advance a broad-spectrum, oligomannuronic acid-based semisynthe...